Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7Z1X

Crystal structure of human Gasdermin D complexed with nanobodies VHH-2 and VHH-6

Summary for 7Z1X
Entry DOI10.2210/pdb7z1x/pdb
DescriptorGasdermin-D, VHH-2, VHH-6, ... (4 entities in total)
Functional Keywordsgasdermin d, gsdmd, nanobody, vhh, inflammation, pyroptosis, immune system
Biological sourceHomo sapiens (human)
More
Total number of polymer chains6
Total formula weight157390.29
Authors
Kopp, A.,Hagelueken, G.,Geyer, M. (deposition date: 2022-02-25, release date: 2023-09-06, Last modification date: 2023-12-13)
Primary citationKopp, A.,Hagelueken, G.,Jamitzky, I.,Moecking, J.,Schiffelers, L.D.J.,Schmidt, F.I.,Geyer, M.
Pyroptosis inhibiting nanobodies block Gasdermin D pore formation.
Nat Commun, 14:7923-7923, 2023
Cited by
PubMed Abstract: Human Gasdermin D (GSDMD) is a key mediator of pyroptosis, a pro-inflammatory form of cell death occurring downstream of inflammasome activation as part of the innate immune defence. Upon cleavage by inflammatory caspases in the cytosol, the N-terminal domain of GSDMD forms pores in the plasma membrane resulting in cytokine release and eventually cell death. Targeting GSDMD is an attractive way to dampen inflammation. In this study, six GSDMD targeting nanobodies are characterized in terms of their binding affinity, stability, and effect on GSDMD pore formation. Three of the nanobodies inhibit GSDMD pore formation in a liposome leakage assay, although caspase cleavage was not perturbed. We determine the crystal structure of human GSDMD in complex with two nanobodies at 1.9 Å resolution, providing detailed insights into the GSDMD-nanobody interactions and epitope binding. The pore formation is sterically blocked by one of the nanobodies that binds to the oligomerization interface of the N-terminal domain in the multi-subunit pore assembly. Our biochemical and structural findings provide tools for studying inflammasome biology and build a framework for the design of GSDMD targeting drugs.
PubMed: 38040708
DOI: 10.1038/s41467-023-43707-z
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.86 Å)
Structure validation

226707

數據於2024-10-30公開中

PDB statisticsPDBj update infoContact PDBjnumon